
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
在2023年第19届年度世界研讨会上公布数据 2023年2月24日,东京 -...
Read more about 安斯泰来宣布研究性AT845在治疗晚发型庞贝氏症成人患者的FORTIS临床实验研究的最新初步安全性和疗效数据
东京,2023年2月13日——安斯泰来制药公司(TSE:...
数据显示,研究性zolbetuximab将疾病进展或死亡风险降低了24.9% 研究对Claudin...
Read more about 安斯泰来在2023年美国临床肿瘤学会(ASCO)胃肠道肿瘤研讨会上展示Zolbetuximab三期试验积极研究结果
东京,2023年1月19日 -...
